Tweets
Sunday: ACR 2022 Daily Recap https://t.co/9naWAYwJIV
Dr. John Cush @RheumNow ( View Tweet )
3 years 8 months ago
#ClinicalPearl woman with non-radiographic axSpA have LESS inactive disease vs MEN but NOT true if radiographic axSpA. 5 yr global study N=2633, independent of TNFi use - not sure why there are differences. Misclassification dx- unlikely. abst#1614 #ACR22 #ACRBest @RheumNowNews https://t.co/coNjwHOkLP
Janet Pope @Janetbirdope ( View Tweet )
3 years 8 months ago
Lifetime career achievement ✔️ - first author of a paper in ACR year in review #ACR22 https://t.co/M5GrOcWY5X
Richard Conway @RichardPAConway ( View Tweet )
3 years 8 months ago
$26,000 was saved over 3 months when this health system implemented change on how ENA panels were ordered (could only be obtained if ANA +); intervention aimed at inappropriate testing by ortho, IM, family med and neuro abst#0058 #ACR22 @rheumnow https://t.co/GoDHat6N3v
TheDaoIndex @KDAO2011 ( View Tweet )
3 years 8 months ago
Pike et al. Deucravactinib (TYK2i) in SLE. + on SRI(4) week 32. + SRI(4),BICLA, LLDAS, CLASI-50, swollen and tender joint counts week 48. Strange, the lowest dose (3mg bd) seems best. @RheumNow #ACR22 Abstr#1117 #ACRbest https://t.co/o4902tvZs8 https://t.co/t8oeMRGUS7
Richard Conway @RichardPAConway ( View Tweet )
3 years 8 months ago
@RheumNow interview with Dr. Lauren Smith on race differences in MMF responses in systemic sclerosis at #ACR22
@jhrheumatology @JHRheumFellows
https://t.co/aSRHiJoIkE
Eric Dein @ericdeinmd ( View Tweet )
3 years 8 months ago
Karmacharya et al. Multimorbidity in PsO strongly influences incident PsA, >=2 comorbidities HR 2.53, >=5 comorbidities HR 3.19. Also higher for non-white, HR 4.02, and decreased with age. @RheumNow #ACR22 Abstr#1506 https://t.co/OFobRzhQVL https://t.co/IP08XlD66H
Richard Conway @RichardPAConway ( View Tweet )
3 years 8 months ago
2000 IU/day vitamin D led to significantly reduced incidence of autoimmune diseases in Abs 1200 over 5.3 years, but after trial termination, protective effects dissipated and were no longer significant. #ACR22 @RheumNow https://t.co/sLwoxeCR3y https://t.co/47wpWXF1W7
Dr. Rachel Tate @uptoTate ( View Tweet )
3 years 8 months ago
HCQ does not prevent RA in CCP+ pts w/out clinical arthritis!
Stop RA: RCT HCQ vs. PBO in pts at-risk
Interim analysis 140+ pts
RA development HCQ 34% vs. PBO 36%
Trial interrupted as met futility criteria.
https://t.co/n31OmsjLhM
Abs#1604 #ACR22 @RheumNow #ACRBest https://t.co/NVYS8kB5to
Aurelie Najm @AurelieRheumo ( View Tweet )
3 years 8 months ago
2022 ACR G/L for Integrative RA Intervent #ACR22
1 strong rec: consistent exercisee
27 conditional recs:
Rehab, Mediterr diet, against other diets, self-mgmt/CBT/acupunct
Conditional against electrotherapy, chiropractor
No rec for diet supplem
BMI, 🚬: no RA spec recomm
@RheumNow https://t.co/cVFr6beQuJ
Eric Dein @ericdeinmd ( View Tweet )
3 years 8 months ago
Patel @draditipatel et al. Delay in starting ACE-I in Scleroderma Renal Crisis increased need for dialysis 75.6% vs 16.7%, p=0.023. No effect on overall survival. 5-year mortality 70%, 1 year mortality 58%. @RheumNow #ACR22 Abstr#1530 https://t.co/cdYhEtqcHT https://t.co/lDWJto1cF0
Richard Conway @RichardPAConway ( View Tweet )
3 years 8 months ago
Mease et al. PsA - Early DMARD initiators (=<1 year following diagnosis) greater improvement in outcomes than late initiators (at least in MDA) in CorEvitas. @RheumNow #ACR22 Abstr#1493 https://t.co/oadxbG8TKS https://t.co/245xVTcKx1
Richard Conway @RichardPAConway ( View Tweet )
3 years 8 months ago
